SCHEMBL516845

SCHEMBL516845

NC(=O)Nc1ccc2ccccc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.65
NPC1 O15118 10/20 0.65
MAPT P10636 3/20 0.65
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
POLB P06746 2/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
CYP1A2 P05177 2/20 0.59
KDM4E B2RXH2 2/20 0.59
ALDH1A1 P00352 1/20 0.59
CYP2C19 P33261 1/20 0.59
HIF1A Q16665 1/20 0.59
SIGMAR1 Q99720 1/20 0.57
CA2 P00918 2/20 0.57
GAA P10253 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
GFER P55789 1/20 0.55
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032426 0.85 RAB9A (0.61) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL9547503 0.83 RAB9A (0.89) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL3072886 0.82 RAB9A (0.57) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL3608965 0.82 RAB9A (0.67) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL1672113 0.82 RAB9A (0.72) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL3294926 0.81 KDM4E (0.59) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL15601787 0.81 KIF11 (0.59) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL8596702 0.81 RAB9A (0.71) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL6409623 0.80 RAB9A (0.56) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL651822 0.80 ALDH1A1 (0.61) RAB9ANPC1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2836485-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS Polyphor Ag (CH) 2015-02-18 EP claimed
WO-2013139697-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2013-09-26 WO claimed
CN-101108813-B Method of manufacturing 1-(2-methoxyphenyl)-3-naphthyl group-2-urea LUOYANG PULIKE BIOLOGY ENGINEERING CO LTD 2010-05-12 CN claimed
CN-101108813-A Method of manufacturing 1-(2-methoxyphenyl)-3-naphthyl group-2-urea LUOYANG PULIKE BIOLOGY ENGINEE (CN) 2008-01-23 CN claimed
EP-1828169-A2 UREA INHIBITORS OF MAP KINASES Locus Pharmaceuticals, Inc. (US) 2007-09-05 EP claimed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 WO claimed
JP-2004534046-A 2004-11-11 JP claimed
CN-119452084-A Oligonucleotide compositions and methods thereof 波涛生命科学有限公司 2025-02-14 CN disclosed
CN-119317632-A Oligonucleotide compositions and methods relating thereto 波涛生命科学有限公司 2025-01-14 CN disclosed
US-12145913-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2024-11-19 US disclosed
CN-117003802-B Sulfonamide derivative containing glucosamine as well as preparation method and application thereof 沈阳药科大学 2024-08-13 CN disclosed
EP-4404942-A2 COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2024-07-31 EP disclosed
CN-117447399-A Naphthalene formylhydrazine compound and preparation method and application thereof 上海应用技术大学 2024-01-26 CN disclosed
US-4891069-A CATALYST FOR REDUCTION OF METAL COMPOUND BY GENERATED HYDROGEN TECHNO INSTRUMENTS INVESTMENTS 1983 LTD. (IL) 1990-01-02 US disclosed
US-4816070-A PRINTED CIRCUITS, ADHESION TECHO INSTRUMENTS INVESTMENTS LTD. (IL) 1989-03-28 US disclosed
US-4790912-A ELECTROLYTICALLY-GENERATED HYDROGEN AND CATALYST CONVERT METAL SALT IN BATH TO METAL TECHNO-INSTRUMENTS INVESTMENTS LTD. (IL) 1988-12-13 US disclosed
US-4749449-A PLATING ON CATALYZED THROUGH HOLE WALL IN PATTERENED CONDUCTIVE AND INSULATING LAYERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-06-07 US disclosed
US-4715894-A AMINIMIZATION OF SMEAR TECHNO INSTRUMENTS INVESTMENTS 1983 LTD. (IL) 1987-12-29 US disclosed
US-4657632-A CONTAINING A THIOUREA AND A UREA COMPOUND TECHNO INSTRUMENTS INVESTMENTS 1983 LTD. (IL) 1987-04-14 US disclosed
EP-0216531-A1 Use of immersion tin and tin alloys as a bonding medium for multilayer circuits TECHNO INSTRUMENTS INVESTMENTS 1983 LTD. (IL) 1987-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12145913-B2 Inhibition of Olig2 activity POU2F2, POU2F1, PLP2 RAB9A 3701/4885NPC1 4540/4885MAPT 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.